Enterprise Value
-46.08M
Cash
192.7M
Avg Qtr Burn
-21.98M
Short % of Float
8.20%
Insider Ownership
14.08%
Institutional Own.
71.38%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
mecbotamab vedotin (BA3011) (anti-AXL ADC) Details Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer | Phase 2 Interim update | |
ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Solid tumor/s, Ovarian cancer, Non-small cell lung carcinoma, Melanoma, Eye disease , Leber congenital amaurosis, Cancer | Phase 2 Interim update | |
BA3071 (CAB anti-CTLA-4 antibody) Details Solid tumor/s, Cancer | Phase 1 Data readout |